The sickle cell disease treatment market size has grown rapidly in recent years. It will grow from $3.51 billion in 2025 to $4.11 billion in 2026 at a compound annual growth rate (CAGR) of 17.3%. The growth in the historic period can be attributed to high prevalence in Africa and Americas, limited treatment availability, reliance on blood transfusions, growth in hematology research, lack of early diagnostic awareness.
The sickle cell disease treatment market size is expected to see rapid growth in the next few years. It will grow to $7.99 billion in 2030 at a compound annual growth rate (CAGR) of 18.1%. The growth in the forecast period can be attributed to emergence of gene therapy solutions, expansion of biologics and targeted drugs, integration of predictive diagnostics, increase in global healthcare initiatives, personalized treatment plans for patients. Major trends in the forecast period include development of gene-editing therapies, increasing availability of hydroxyurea, expansion of blood transfusion management, adoption of advanced diagnostics for early detection, growth in patient support and disease management programs.
The increasing use of blood and bone marrow transplants is expected to drive the growth of the sickle cell disease treatment market in the coming years. Blood and bone marrow transplantation is a medical procedure in which damaged or diseased blood-forming cells are replaced with healthy ones. Bone marrow transplants are used to treat sickle cell disease and certain cancers by infusing healthy marrow cells after eliminating abnormal cells from the patient’s bone marrow. These replacement cells may be sourced from the patient themselves (autologous transplant) or from a compatible donor (allogeneic transplant). For example, in June 2024, according to the National Transplant Organization (ONT), a Spain-based independent coordinating body, Spain added 23,686 donors to the Spanish Bone Marrow Donor Registry in 2023, representing an 8% increase compared to 2022, and recorded a total of 3,717 hematopoietic stem cell transplants, equivalent to 77.4 transplants per million population. Thus, the growing number of blood and bone marrow transplants is supporting the expansion of the sickle cell disease treatment market.
Companies operating in the sickle cell disease treatment market are increasingly focusing on the development of oral suspension formulations to improve patient adherence, enhance therapeutic effectiveness, and offer more convenient treatment options, particularly for pediatric and elderly populations. Oral suspension medications are liquid formulations containing dispersed solid particles, making them easier to swallow for patients who have difficulty taking tablets or capsules. For instance, in March 2024, Akums Drugs and Pharmaceuticals Ltd., an India-based pharmaceutical manufacturing company, introduced a room-temperature-stable oral suspension of Hydroxyurea. This affordable treatment for sickle cell disease is designed to improve accessibility in India and is priced at less than 1% of imported alternatives. It enables accurate dosing through oral syringes, supports patients across all age groups, and does not require cold storage.
In December 2023, Vertex Pharmaceuticals, a US-based biopharmaceutical company, partnered with Editas Medicine to utilize Editas’s Cas9 gene-editing technology for the development of ex vivo therapies, including CASGEVY, targeting sickle cell disease and beta thalassemia. This collaboration aims to accelerate Vertex’s precision gene therapy pipeline. Editas Medicine is a US-based company specializing in CRISPR/Cas9 and Cas12a genome-editing platforms for therapeutic applications.
Major companies operating in the sickle cell disease treatment market are Sun Pharmaceutical Industries Ltd., Pfizer Inc., Johnson & Johnson Private Limited, Merck & Co Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Vertex Pharmaceuticals Incorporated, Global Blood Therapeutics Inc., Acceleron Pharma Inc., Sangamo Therapeutics Inc., Medunik USA Inc., Zydus Cadila Healthcare Ltd., Graphite Bio Inc., Addmedica, Emmaus Medical Inc., Bluebird bio Inc., CRISPR Therapeutics AG, GlycoMimetics Inc., Mast Therapeutics Inc.
North America was the largest region in the sickle cell disease treatment market in 2025. The regions covered in the sickle cell disease treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the sickle cell disease treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have influenced the sickle cell disease treatment market by raising the prices of imported pharmaceuticals, blood-processing equipment, biologics, and gene-based therapy components. Hospitals and specialty clinics in Asia-Pacific and emerging economies that rely on international suppliers face increased treatment costs. These effects are especially visible in pharmacotherapy and transfusion-related segments. However, tariffs are stimulating domestic drug manufacturing and biotechnology investment, which is supporting long-term growth and treatment availability in the sickle cell disease treatment market.
The sickle cell disease treatment market research report is one of a series of new reports that provides sickle cell disease treatment market statistics, including sickle cell disease treatment industry global market size, regional shares, competitors with a sickle cell disease treatment market share, detailed sickle cell disease treatment market segments, market trends and opportunities, and any further data you may need to thrive in the sickle cell disease treatment industry. This sickle cell disease treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Sickle cell disease (SCD), also referred to as sickle cell anemia, is a genetic disorder that affects hemoglobin, the protein found in red blood cells. A mutation in the hemoglobin gene leads to the production of abnormal hemoglobin, known as hemoglobin S (HbS), in individuals with sickle cell disease. Treatment for sickle cell disease focuses on removing blockages, improving blood flow, and repairing damaged tissues.
The main treatment modalities for sickle cell disease include blood transfusion, pharmacotherapy, and bone marrow transplantation. Blood transfusion involves the transfer of blood or blood products from a donor to a recipient. The disease types include sickle cell anemia, hemoglobin sickle C disease (HBsC), and others, with routes of administration such as oral and parenteral. The primary end-users of these treatments are hospitals, specialty clinics, and others.
The sickle cell disease treatment market consists of revenues earned by entities by providing services such as oxygen therapy, pulmonary hypertension management and pain management. The market value includes the value of related goods sold by the service provider or included within the service offering. The sickle cell disease treatment market also includes sales of hydroxyurea, L-glutamine and voxlelotor. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The sickle cell disease treatment market size is expected to see rapid growth in the next few years. It will grow to $7.99 billion in 2030 at a compound annual growth rate (CAGR) of 18.1%. The growth in the forecast period can be attributed to emergence of gene therapy solutions, expansion of biologics and targeted drugs, integration of predictive diagnostics, increase in global healthcare initiatives, personalized treatment plans for patients. Major trends in the forecast period include development of gene-editing therapies, increasing availability of hydroxyurea, expansion of blood transfusion management, adoption of advanced diagnostics for early detection, growth in patient support and disease management programs.
The increasing use of blood and bone marrow transplants is expected to drive the growth of the sickle cell disease treatment market in the coming years. Blood and bone marrow transplantation is a medical procedure in which damaged or diseased blood-forming cells are replaced with healthy ones. Bone marrow transplants are used to treat sickle cell disease and certain cancers by infusing healthy marrow cells after eliminating abnormal cells from the patient’s bone marrow. These replacement cells may be sourced from the patient themselves (autologous transplant) or from a compatible donor (allogeneic transplant). For example, in June 2024, according to the National Transplant Organization (ONT), a Spain-based independent coordinating body, Spain added 23,686 donors to the Spanish Bone Marrow Donor Registry in 2023, representing an 8% increase compared to 2022, and recorded a total of 3,717 hematopoietic stem cell transplants, equivalent to 77.4 transplants per million population. Thus, the growing number of blood and bone marrow transplants is supporting the expansion of the sickle cell disease treatment market.
Companies operating in the sickle cell disease treatment market are increasingly focusing on the development of oral suspension formulations to improve patient adherence, enhance therapeutic effectiveness, and offer more convenient treatment options, particularly for pediatric and elderly populations. Oral suspension medications are liquid formulations containing dispersed solid particles, making them easier to swallow for patients who have difficulty taking tablets or capsules. For instance, in March 2024, Akums Drugs and Pharmaceuticals Ltd., an India-based pharmaceutical manufacturing company, introduced a room-temperature-stable oral suspension of Hydroxyurea. This affordable treatment for sickle cell disease is designed to improve accessibility in India and is priced at less than 1% of imported alternatives. It enables accurate dosing through oral syringes, supports patients across all age groups, and does not require cold storage.
In December 2023, Vertex Pharmaceuticals, a US-based biopharmaceutical company, partnered with Editas Medicine to utilize Editas’s Cas9 gene-editing technology for the development of ex vivo therapies, including CASGEVY, targeting sickle cell disease and beta thalassemia. This collaboration aims to accelerate Vertex’s precision gene therapy pipeline. Editas Medicine is a US-based company specializing in CRISPR/Cas9 and Cas12a genome-editing platforms for therapeutic applications.
Major companies operating in the sickle cell disease treatment market are Sun Pharmaceutical Industries Ltd., Pfizer Inc., Johnson & Johnson Private Limited, Merck & Co Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Vertex Pharmaceuticals Incorporated, Global Blood Therapeutics Inc., Acceleron Pharma Inc., Sangamo Therapeutics Inc., Medunik USA Inc., Zydus Cadila Healthcare Ltd., Graphite Bio Inc., Addmedica, Emmaus Medical Inc., Bluebird bio Inc., CRISPR Therapeutics AG, GlycoMimetics Inc., Mast Therapeutics Inc.
North America was the largest region in the sickle cell disease treatment market in 2025. The regions covered in the sickle cell disease treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the sickle cell disease treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have influenced the sickle cell disease treatment market by raising the prices of imported pharmaceuticals, blood-processing equipment, biologics, and gene-based therapy components. Hospitals and specialty clinics in Asia-Pacific and emerging economies that rely on international suppliers face increased treatment costs. These effects are especially visible in pharmacotherapy and transfusion-related segments. However, tariffs are stimulating domestic drug manufacturing and biotechnology investment, which is supporting long-term growth and treatment availability in the sickle cell disease treatment market.
The sickle cell disease treatment market research report is one of a series of new reports that provides sickle cell disease treatment market statistics, including sickle cell disease treatment industry global market size, regional shares, competitors with a sickle cell disease treatment market share, detailed sickle cell disease treatment market segments, market trends and opportunities, and any further data you may need to thrive in the sickle cell disease treatment industry. This sickle cell disease treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Sickle cell disease (SCD), also referred to as sickle cell anemia, is a genetic disorder that affects hemoglobin, the protein found in red blood cells. A mutation in the hemoglobin gene leads to the production of abnormal hemoglobin, known as hemoglobin S (HbS), in individuals with sickle cell disease. Treatment for sickle cell disease focuses on removing blockages, improving blood flow, and repairing damaged tissues.
The main treatment modalities for sickle cell disease include blood transfusion, pharmacotherapy, and bone marrow transplantation. Blood transfusion involves the transfer of blood or blood products from a donor to a recipient. The disease types include sickle cell anemia, hemoglobin sickle C disease (HBsC), and others, with routes of administration such as oral and parenteral. The primary end-users of these treatments are hospitals, specialty clinics, and others.
The sickle cell disease treatment market consists of revenues earned by entities by providing services such as oxygen therapy, pulmonary hypertension management and pain management. The market value includes the value of related goods sold by the service provider or included within the service offering. The sickle cell disease treatment market also includes sales of hydroxyurea, L-glutamine and voxlelotor. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Sickle Cell Disease Treatment Market Characteristics
3. Sickle Cell Disease Treatment Market Supply Chain Analysis
4. Global Sickle Cell Disease Treatment Market Trends and Strategies
5. Sickle Cell Disease Treatment Market Analysis of End Use Industries
7. Global Sickle Cell Disease Treatment Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Sickle Cell Disease Treatment Total Addressable Market (TAM) Analysis for the Market
9. Sickle Cell Disease Treatment Market Segmentation
10. Sickle Cell Disease Treatment Market Regional and Country Analysis
11. Asia-Pacific Sickle Cell Disease Treatment Market
12. China Sickle Cell Disease Treatment Market
13. India Sickle Cell Disease Treatment Market
14. Japan Sickle Cell Disease Treatment Market
15. Australia Sickle Cell Disease Treatment Market
16. Indonesia Sickle Cell Disease Treatment Market
17. South Korea Sickle Cell Disease Treatment Market
18. Taiwan Sickle Cell Disease Treatment Market
19. South East Asia Sickle Cell Disease Treatment Market
20. Western Europe Sickle Cell Disease Treatment Market
21. UK Sickle Cell Disease Treatment Market
22. Germany Sickle Cell Disease Treatment Market
23. France Sickle Cell Disease Treatment Market
24. Italy Sickle Cell Disease Treatment Market
25. Spain Sickle Cell Disease Treatment Market
26. Eastern Europe Sickle Cell Disease Treatment Market
27. Russia Sickle Cell Disease Treatment Market
28. North America Sickle Cell Disease Treatment Market
29. USA Sickle Cell Disease Treatment Market
30. Canada Sickle Cell Disease Treatment Market
31. South America Sickle Cell Disease Treatment Market
32. Brazil Sickle Cell Disease Treatment Market
33. Middle East Sickle Cell Disease Treatment Market
34. Africa Sickle Cell Disease Treatment Market
36. Sickle Cell Disease Treatment Market Competitive Landscape and Company Profiles
37. Sickle Cell Disease Treatment Market Other Major and Innovative Companies
40. Sickle Cell Disease Treatment Market High Potential Countries, Segments and Strategies
41. Appendix
Executive Summary
Sickle Cell Disease Treatment Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses sickle cell disease treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for sickle cell disease treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The sickle cell disease treatment market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Treatment Modality: Blood Transfusion; Pharmacotherapy; Bone Marrow Transplant2) By Disease Type: Sickle Cell Anemia; Hemoglobin Sickle C Disease (HbSC); Other Disease Types
3) By Route Of Administration: Oral; Parenteral
4) By End-User: Hospitals; Specialty Clinics; Other End-Users
Subsegments:
1) By Blood Transfusion: Regular Blood Transfusion; Exchange Transfusion2) By Pharmacotherapy: Hydroxyurea; L-Glutamine; Voxelotor; Crizanlizumab
3) By Bone Marrow Transplant: Allogeneic Transplant; Autologous Transplant
Companies Mentioned: Sun Pharmaceutical Industries Ltd.; Pfizer Inc.; Johnson & Johnson Private Limited; Merck & Co Inc.; Novartis AG; Sanofi S.A.; Bristol-Myers Squibb Company; AstraZeneca plc; Eli Lilly and Company; Gilead Sciences Inc.; Amgen Inc.; Baxter International Inc.; Teva Pharmaceutical Industries Ltd.; Vertex Pharmaceuticals Incorporated; Global Blood Therapeutics Inc.; Acceleron Pharma Inc.; Sangamo Therapeutics Inc.; Medunik USA Inc.; Zydus Cadila Healthcare Ltd.; Graphite Bio Inc.; Addmedica; Emmaus Medical Inc.; Bluebird bio Inc.; CRISPR Therapeutics AG; GlycoMimetics Inc.; Mast Therapeutics Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Sickle Cell Disease Treatment market report include:- Sun Pharmaceutical Industries Ltd.
- Pfizer Inc.
- Johnson & Johnson Private Limited
- Merck & Co Inc.
- Novartis AG
- Sanofi S.A.
- Bristol-Myers Squibb Company
- AstraZeneca plc
- Eli Lilly and Company
- Gilead Sciences Inc.
- Amgen Inc.
- Baxter International Inc.
- Teva Pharmaceutical Industries Ltd.
- Vertex Pharmaceuticals Incorporated
- Global Blood Therapeutics Inc.
- Acceleron Pharma Inc.
- Sangamo Therapeutics Inc.
- Medunik USA Inc.
- Zydus Cadila Healthcare Ltd.
- Graphite Bio Inc.
- Addmedica
- Emmaus Medical Inc.
- Bluebird bio Inc.
- CRISPR Therapeutics AG
- GlycoMimetics Inc.
- Mast Therapeutics Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 4.11 Billion |
| Forecasted Market Value ( USD | $ 7.99 Billion |
| Compound Annual Growth Rate | 18.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 27 |
